Global Bovine High-Mountain Disease Market Size study, by Drug Class (Bovine High-Mountain Disease Diuretics, Bovine High-Mountain Disease Antibiotics, Bovine High-Mountain Disease Appetite Stimulators, Other Bovine High-Mountain Disease Drugs), by Distribution Channel (Bovine High-Mountain Disease Drugs Sales via Veterinary Hospitals, Bovine High-Mountain Disease Drugs Sales via Veterinary Clinics, Bovine High-Mountain Disease Drugs Sales via Veterinary Pharmaceutical Stores, Bovine High-Mountain Disease Drugs Sales via Other Distribution Channels) and Regional Forecasts 2022-2028
Global Bovine High-Mountain Disease Market is valued at approximately USD 4.1 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 5.25 % over the forecast period 2022-2028. Bovine high-mountain disease (BHMD), commonly known as brisket disease, is a serious disease that kills a lot of calves. Right heart failure is the most common cause of bovine high-mountain illness, which is characterised by hypoxic pulmonary hypertension at high altitudes. Bovine high-mountain illness is a disease that affects cattle of all ages and breeds at elevations above 7,000 feet. The incidence rate of bovine respiratory illness is closely proportional to the elevation. High altitude, physiologic, genetic, and environmental variables are all linked to bovine high-mountain illness. It's also been suggested that bovine high-mountain disease is linked to bovine respiratory disease mortality and morbidity (BRD). Weakness, collapse, diarrhoea, bulging eyes, and swelling are some of the symptoms linked with bovine high-mountain sickness. Rising incidence of congestive heart failure, rising prevalence of respiratory diseases, genetic susceptibility in animals and rising awareness and initiatives among key players have driven the adoption of Bovine High-Mountain Disease across the projected period. For Instance: Zoetis Inc. unveiled its long-term sustainability goals in March 2021, which were based on the company's mission to nourish the earth and humanity through increasing animal care. Zoetis' specific commitments to Communities, Animals, and the Planet, including support for 10 of the 17 United Nations Sustainable Development Goals, are brought to life under the banner Driven to Care (SDGs). Also, rise in government funding for the treatment and rising investment to set up Veterinary Hospital is most likely to boost the overall growth of the Bovine High-Mountain Disease market. However, lack of information and knowledge about the disease and high cost of treatment can obstruct the market's expansion over the projection period of 2022-2028.
The key regions considered for the global Bovine High-Mountain Disease market study include Asia Pacific, North America, Europe, Latin America and Rest of the World. North America is the leading region across the world. Presence of high elevation is driving the market growth in North America. Whereas, Asia Pacific is also anticipated to exhibit the highest growth rate over the forecast period 2022-2028. The market is expected to grow during the projected period, due rising government investment in the treatment of Bovine-high Mountain Disease.
Major market players included in this report are:
Zoetis Inc.
Bayer AG
Eli Lilly and Company
Dechra Pharmaceuticals
Merck and Co. Inc.
Heathrow Scientific
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Drug Class:
Bovine High-Mountain Disease Diuretics
Bovine High-Mountain Disease Antibiotics
Bovine High-Mountain Disease Appetite Stimulators
Other Bovine High-Mountain Disease Drugs
By Distribution Channel:
Bovine High-Mountain Disease Drugs Sales via Veterinary Hospitals
Bovine High-Mountain Disease Drugs Sales via Veterinary Clinics
Bovine High-Mountain Disease Drugs Sales via Veterinary Pharmaceutical Stores
Bovine High-Mountain Disease Drugs Sales via Other Distribution Channels
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World
Furthermore, years considered for the study are as follows:
Historical year – 2018, 2019, 2020
Base year – 2021
Forecast period – 2022 to 2028
Target Audience of the Global Bovine High-Mountain Disease Market in Market Study:
Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors
Companies Mentioned
Zoetis Inc.
Bayer AG
Eli Lilly and Company
Dechra Pharmaceuticals
Merck and Co. Inc.
Heathrow Scientific
Please note:The single user license is non-downloadable and non-printable. Global Site license will allow these actions.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook